化疗联合帕博利珠单抗对晚期非小细胞肺癌患者的影响

Effect of Chemotherapy Combined with Pembrolizumab on Patients with Advanced Non-small Cell Lung Cancer

目的:探讨化疗联合帕博利珠单抗对晚期非小细胞肺癌患者的影响。方法:选取2019年1月-2021年1月60例茂名市人民医院收治的晚期非小细胞肺癌患者作为研究对象。采用随机数字表法将其分为对照组和研究组,各30例。对照组给予常规化疗,研究组给予化疗联合帕博利珠单抗治疗。比较两组治疗前后免疫功能、生活质量、临床疗效及不良反应。观察两组中位无进展生存时间(PFS)。结果:治疗后研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均显著高于对照组,CD8^(+)水平低于对照组(P<0.05)。治疗后研究组肺癌患者生活量表(FACT-L)、健康状况调查简表(SF-36)评分均明显高于对照组(P<0.05)。治疗后研究组客观缓解率为76.67%,明显高于对照组的50.00%(P<0.05)。研究组白细胞减少发生率明显低于对照组(P<0.05),两组血小板减少、恶心呕吐、皮疹、肝肺功能异常、甲状腺功能异常发生率比较差异均无统计学意义(P>0.05)。对照组中位PFS为5.2个月,研究组中位PFS为9个月。结论:对晚期非小细胞肺癌患者采取化疗联合帕博利珠单抗治疗具有积极效果,不仅能够改善免疫功能与生活质量,同时能够提高病灶客观缓解率及中位FPS。

Objective:To investigate the effect of chemotherapy combined with Pembrolizumab on patients with advanced nonsmall cell lung cancer.Method:A total of 60 patients with advanced non-small cell lung cancer admitted to Maoming People’s Hospital from January 2019 to January 2021 were selected as the research objects.They were divided into control group and study group by random number table method,with 30 cases in each group.The control group was given the routine chemotherapy,and the study group was given the chemotherapy combined with Pembrolizumab treatment.The immune function,quality of life before and after treatment,clinical efficacy and adverse reactions were compared between the two groups.The median progression free survival(PFS)of the two groups was observed.Result:After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the study group were significantly higher than those in the control group,and the level of CD8^(+)was lower than that in the control group(P<0.05).After treatment,the scores of life scale for lung cancer patients(FACT-L),short-form of health survey(SF-36)in the study group were significantly higher than those in the control group(P<0.05).After treatment,the objective remission rate in the study group was 76.67%,which was significantly higher than 50.00% in the control group(P<0.05).The incidences of leucopenia in the study group was significantly lower than that in the control group(P<0.05).There were no significant differences in the incidences of thrombocytopenia,nausea and vomiting,rash,abnormal liver and lung function and abnormal thyroid function between the two groups(P>0.05).The median PFS was 5.2 months in the control group and 9 months in the study group.Conclusion:Chemotherapy combined with Pembrolizumab has a positive effect in the treatment of patients with advanced non-small cell lung cancer.It can not only improve immune function and quality of life,but also improve the objective remission rate of lesions.